Custom Search

News

Wednesday 05 April 2006

Geodon Effective In Treating Schizophrenia Symptoms With A Postive Effect On Patients' Weight, Cholesterol And Triglycerides, Study Shows

By: MediLexicon News

Pfizer today issued the following statement upon publication of results from the second phase of the National Institute of Mental Health (NIMH) study, Antipsychotic Trials of Intervention Effectiveness (CATIE), in patients with schizophrenia.

Phase II of CATIE evaluated treatment pathways of patients who discontinued treatment in phase I because their symptoms were not adequately controlled or they could not tolerate the medicine. Pfizer's Geodon® (ziprasidone HCL) was one of four medications evaluated in the tolerability pathway, which included patients who discontinued phase I due to intolerability or lack of efficacy.

“A significant finding in both phases of CATIE is that many patients with schizophrenia discontinued their treatment for a variety of reasons,” said Dr. Cathryn Clary, senior vice president, Pfizer medical. “CATIE highlights the need to have multiple treatment options and open access to these medicines so physicians can tailor a treatment that is both effective and tolerable to the individual patient.”

In phase II, Geodon was shown to be effective in treating symptoms of schizophrenia. In addition, patients taking Geodon experienced a decrease in weight and an improvement in metabolic parameters, including cholesterol and triglycerides. People with schizophrenia are more prone to obesity, elevated levels of cholesterol and diabetes, which pose a long-term cardiovascular risk.

The primary endpoint of the study was the length of time patients stayed on treatment, or time to discontinuation. Patients stayed on risperidone and olanzapine longer than quetiapine and ziprasidone.

“The doses of the medication used in CATIE may have affected how long patients stayed on their treatment,” said Clary. “Geodon was the only medicine dosed lower (116 mg/day) than the current average dose used by physicians (138 mg/day) while olanzapine and risperidone were used at higher than current average doses. Studies have demonstrated the effectiveness of Geodon at doses up to 160 mg a day. The right dose of medicine is critical to successful treatment of patients with this chronic and significant disease.”

The NIMH-funded CATIE study sought to evaluate and compare the long-term clinical effectiveness (efficacy and tolerability) of the newer, so-called atypical antipsychotics olanzapine, quetiapine, risperidone, and ziprasidone, and clozapine, an older antipsychotic, in treating schizophrenia.

Read Original Text

Use of this site is subject to the following terms of use